| abstract |
The present invention relates to new imidazolidinonyl aminopyrimidine compounds, which are believed to have clinical use for the treatment of cancer through the inhibition of Plk1, wherein: R1 is hydrogen, hydroxy, halo, methyl, C1-C2 alkoxy, amino or methylamino; R2 is hydrogen, halo or cyano; R3 is hydrogen or halo; R4 is hydrogen, halo or methyl; provided that at least two of R1, R2, R3 and R4 are hydrogen; R5 is hydrogen, halo or methyl; or a pharmaceutically acceptable salt thereof. |